19 Jul Capstan Therapeutics
Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D
Oct. 7 | 4:15pm | FLW Ballroom G
San Diego, CA
(Private)
Capstan’s mission is to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies. Our core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, and are designed to deliver payloads, including mRNA or gene editing tools, capable of reprograming specific cell types in vivo. Our technology enables us to pursue two distinct approaches to treating disease: engineering immune cells and targeting pathogenic cells. In vivo engineering of immune cells: we can deliver mRNA-encoded CARs to specific subsets of immune cells, programming them to eliminate pathogenic cells (autoimmune or cancerous) that express antigens recognized by the CAR. Targeting of pathogenic cells: by delivering mRNA-encoded gene editing machinery to pathogenic cells, we can modify the cells’ DNA to treat genetic disease. Capstan is a post series B stage company, based in San Diego.
